dydrogesterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids, progestogens | 975 | 152-62-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit OVULATION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 28 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | SOLVAY |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Placenta accreta | 77.65 | 51.69 | 10 | 388 | 191 | 50604535 |
| Ovarian hyperstimulation syndrome | 62.05 | 51.69 | 12 | 386 | 3232 | 50601494 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Placenta accreta | 82.01 | 54.44 | 10 | 336 | 181 | 64498205 |
| Ovarian hyperstimulation syndrome | 61.58 | 54.44 | 11 | 335 | 2834 | 64495552 |
| Maternal exposure during pregnancy | 58.03 | 54.44 | 21 | 325 | 95863 | 64402523 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G03DB01 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnadien derivatives |
| ATC | G03FA14 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations |
| ATC | G03FB08 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D011372 | Progestins |
| CHEBI has role | CHEBI:59826 | progestins |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Progesterone receptor | Nuclear hormone receptor | AGONIST | Ki | 6.90 | IUPHAR | CHEMBL | |||
| Nuclear receptor subfamily 2 group E member 1 | Nuclear hormone receptor | Kd | 4.56 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| N0000167428 | NUI |
| D01217 | KEGG_DRUG |
| C0013340 | UMLSCUI |
| CHEBI:31527 | CHEBI |
| CHEMBL1200853 | ChEMBL_ID |
| DB00378 | DRUGBANK_ID |
| D004394 | MESH_DESCRIPTOR_UI |
| 9051 | PUBCHEM_CID |
| 2878 | IUPHAR_LIGAND_ID |
| 970 | INN_ID |
| 90I02KLE8K | UNII |
| 3706 | RXNORM |
| 001296 | NDDF |
| 126093005 | SNOMEDCT_US |
| 43753001 | SNOMEDCT_US |
Pharmaceutical products:
None